AbbVie | Omløpsmidler



Current Assets Endring Dato
AbbVie USD 25.58B 2.2B 2024-12
Abbott USD 23.66B 146M 2024-12
ALKERMES USD 1.42B 167.74M 2024-12
Amgen USD 29.03B 2.26B 2024-12
AstraZeneca USD 25.83B 1.67B 2024-12
Biogen USD 7.46B 626.3M 2024-12
BioMarin Pharmaceutical USD 3.23B 175.84M 2024-12
Bristol-Myers Squibb USD 29.78B 1.7B 2024-12
Eisai JPY 761.1B 79.19B 2024-12
Eli Lilly USD 32.74B 1.32B 2024-12
Gilead Sciences USD 19.17B 4.39B 2024-12
GlaxoSmithKline GBP 17B 301M 2024-12
J&J USD 55.89B 2.64B 2024-12
Medtronic USD 22.51B 75M 2025-01
Merck USD 38.78B 1.58B 2024-12
Neurocrine Biosciences USD 1.72B 151.9M 2024-12
Novartis USD 29.7B 1.56B 2024-12
Pacira USD 745.13M 55.16M 2024-12
Perrigo USD 2.48B 1.23B 2024-12
Pfizer USD 50.36B 7.14B 2024-12
Regeneron Pharmaceuticals USD 27.21B 7.88B 2024-12
Roche Holding CHF 40.04B 6.41B 2024-12
Sanofi 30.08B 589M 2024-06
UCB EUR 4.79B 1.47B 2024-12
Ultragenyx Pharmaceutical USD 817.12M 17.52M 2024-12
United Therapeutics USD 3.87B 126.5M 2024-12
Vertex Pharmaceuticals USD 9.6B 207.7M 2024-12
Zoetis USD 5.99B 296M 2024-12



AbbVie Omløpsmidler - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - Mar 2025.